Weight‐Reduction and Safety Profile of Once‐Weekly Non‐Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real‐World Retrospective Study

ABSTRACT Background and Aims Semaglutide, a once‐weekly injectable glucagon‐like peptide, showed double‐digit weight reduction with an acceptable safety profile in clinical trials and real‐world studies. The efficacy and safety of non‐comparable biotherapeutic (NCB) semaglutide are not adequately re...

Descrición completa

Detalles Bibliográficos

Principais autores:	Md Rakibul Hasan, Kishore Kumar Shil, Md Shahed‐Morshed
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2026-01-01
Series:	Health Science Reports
Assuntos:	non‐comparable biotherapeutic semaglutide Obesity Semaglutide Weight loss
Acceso en liña:	https://doi.org/10.1002/hsr2.71745
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!